The humble tick isn't often viewed as an ally of human health (see page 524), but one British biotechnology company is banking on its hidden charms. Reading-based Evolutec holds patent rights on a number of proteins found in the saliva of ticks, and some are already showing clinical promise, particularly for the treatment of allergies and inflammation.
展开▼
